## Edgar Filing: BIOGEN IDEC INC. - Form 4

BIOGEN II Form 4 March 21, 2												
FORM										OMB AF	PROVAL	
	UNITED	STATES						NGE CO	OMMISSION	OMB Number:	3235-0287	
Check t		<sup>r</sup> STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									January 31,	
if no lor subject Section Form 4	to <b>STATE</b> 16.										Expires: 2009 Estimated average burden hours per response 0.9	
Form 5 obligation may con <i>See</i> Inst 1(b).	Public U	Itility H	Iol		npan	y Act of 1	Act of 1934, 1935 or Section					
(Print or Type	Responses)											
1. Name and DORSA C.	Address of Reporting AROLINE	Person <u>*</u>	Symbol			I Ticker or		0	5. Relationship of H ssuer	Reporting Pers	on(s) to	
(Last)	(First) (	Middle)	BIOGEN IDEC INC. [BIIB] (Chec 3. Date of Earliest Transaction						(Check	k all applicable)		
BIOGEN IDEC INC., 225 BINNEY 03/20/2 STREET				/2014 -					_X_ Director 10% Owner Officer (give title Other (specify below) below)			
				Month/Day/Year) Applicable Line) _X_ Form filed by					Applicable Line) _X_ Form filed by Oı	oint/Group Filing(Check One Reporting Person More than One Reporting		
	DGE, MA 02142								Person		Jording	
(City)	(State)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or						or Beneficiall	y Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Transaction Date 2A. Deemed Ionth/Day/Year) Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common				Code	V	Amount	(D)	Price	(Instr. 3 and 4)			
Stock	03/20/2014			M <u>(1)</u>		10,000	А	\$ 53.64	24,468	D		
Common Stock	03/20/2014			S <u>(1)</u>		2,200	D	\$ 347.283 (2) (3)	22,268	D		
Common Stock	03/20/2014			S <u>(1)</u>		2,701	D	\$ 348.662 ( <u>3)</u> ( <u>4)</u>	19,567	D		
Common Stock	03/20/2014			S <u>(1)</u>		4,199	D	\$ 349.541 (3) (5)	15,368	D		

#### Edgar Filing: BIOGEN IDEC INC. - Form 4

Common 03/20/2014 Stock	S <u>(1)</u>	900	D	\$ 350.368 (3) (6)	14,468		D
----------------------------	--------------	-----	---	--------------------------	--------	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	if TransactionDerivati Code Securiti ar) (Instr. 8) Acquire or Dispo (D)		Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 53.64	03/20/2014		M <u>(1)</u>	10,000	(7)	01/03/2020	Common Stock	10,000	

# **Reporting Owners**

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
DORSA CAROLINE BIOGEN IDEC INC. 225 BINNEY STREET CAMBRIDGE, MA 02142	Х			
Signatures				
Matthew S. Gilman, Attorney i Dorsa	03/21/2014			
**Signature of Report		Date		

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934

### Edgar Filing: BIOGEN IDEC INC. - Form 4

- (2) This represents the weighted average price for shares purchased at a range between \$347.06 (low) and \$347.95 (high).
- (3) Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- (4) This represents the weighted average price for shares purchased at a range between \$348.09 (low) and \$349.06 (high).
- (5) This represents the weighted average price for shares purchased at a range between \$349.11 (low) and \$350.08 (high).
- (6) This represents the weighted average price for shares purchased at a range between \$350.11 (low) and \$350.85 (high).
- (7) The stock options become exercisable in three (3) equal annual installments commencing one year after the grant date of 01/04/2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.